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Exercise duration (in seconds) by exercise test and QOL score
assessment by Kansas City Cardiomyopathy Questionnaire
(KCCQ) and Serum BNP level. In ivabradine group, patients were
started on ivabradine5 mg in twice daily dose, in addition to OMT.
Patients were followed up for 6 months. At the end of six months,
LV dimensions, LV function, serum BNP levels, QOL and exercise
duration were re-assessed.
Results: At six months, though there was significant reduction of
heart rate (70.60 ± 5.06 vs 91.33 ±8.9, p < 0.0001) and improvement
of QOL score (p¼ 0.004) and NYHA functional Class(p¼ 0.007) with
ivabradine group compared to OMT group, ivabradine failed to
show significant improvement in LVEF(35 ±3.71 vs 33±4.24, p¼NS),
Exercise duration (320 ±130.6 vs 311.79 ±103.60, p¼ 0.663) and BNP
level (248.64 ±175.70 vs 312.57 ±222.6, p¼ 0.22). Subgroup analysis
showed significant improvement in LVEF (35.71±2.98 vs 33.50
±3.73, p¼0.003) in patients with ivabradine who achieved heart
rate less than 70(n¼25). No significant adverse effects on ivabra-
dine therapy were noted at the end of six months.
Conclusions: Ivabradine when added to optimal medical therapy,
in NYHA Functional Class and QoL in patients with ischemic heart
failure. Improvement of Left ventricular function also occurs in
presence of adequate heart rate lowering (HR<70/ min).
Efficacy of levosimendan compared with
dobutamine in low-output heart failure
Anurag Rawat, Aditya Chaudhary
Himalayan Institute of Medical Sciences, India
Background: Levosimendan, a calcium channel sensitiser, im-
proves myocardial contractility without causing an increase in
myocardial oxygen demand. This study was done to compare the
effects of levosimendan and dobutamine on clinical outcome in
patients with low-output heart failure.
Methods: Patients were eligible for participation in this study if
they had symptomatic low output heart failure. Overall 175 pa-
tients were enrolled in this study. Under continuous haemody-
namic monitoring, an initial loading dose of levosimendan of 24
mcg/kg was infused over 10 min, followed by a continuous infu-
sion of 0.1 mcg/kg/min for 24 h. Dobutamine was infused for 24 h
at a dose of 5 mcg/kg/min. The primary endpoint was the pro-
portion of patients with clinical improvement.
Results: 100 patients were given levosimendan and 75 dobut-
amine. The clinical improvement was achieved in 28 (28%) levo-
simendan-group patients and 15 (20%) in the dobutamine group
p¼0.02). At 6 months, 20 (20%) levosimendan-group patients had
died, compared with 25 (33%) in the dobutamine group p¼0.02).
Conclusion: In patients with severe, low-output heart failure,
levosimendan improved clinical outcome more effectively than
dobutamine. Lower mortality was noted in levosimendan group
upto 6 months.
Correlation of clinical spectrum,
echocardiographic, and angiographic patterns in
patients with apical ballooning syndrome in a
tertiary care centre of North India
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S. Takkar, B. Singh, A. Goyal
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Background: A cardiac syndrome of “apical ballooning” is being
increasingly encountered in routine cardiology practice as it
usually mimics acute coronary syndrome at presentation and
therefore mandates demonstration of non critical coronary artery
disease on coronary angiogram for diagnostic confirmation but its
feasibility is scarce in our country. We sought to assimilate clin-
ical, echo-cardiographic and angiographic features of this syn-
drome at a tertiary care setting from carefully selected cases of
apical ballooning and develop an algorithmwhich should help the
emergency physician in making a simpler bedside diagnosis of
this syndrome.
Methods: Patients apparently admitted with acute coronary syn-
drome but subsequently given the diagnosis of transient LV apical
ballooning syndrome at our institution from January 2011 to June
2013 were taken prospectively.
Results: Twelve patients were enrolled, mean age was 50±12
years, 10 (83%) were women. Trigger events could be identified in
9(75%) patients (emotional stress in 3 (25%),post vocal cord sur-
gery in 1(8%), hemiarthroplasty in 1(8%), cervical spine surgery in
1(8%), cervical trauma in 1(8%), gastrointestinal infection in 1 (8%),
road side accident in 1(8%). Presenting symptomswere; chest pain
or discomfort in 3 (25%), NYHA grade III/IV dyspnoea in 9(75 %)
patients. 7 (58%) patients had elevated creatine kinase MB and
troponin T levels, but the levels were usually only marginally
elevated. Electrocardiographic changes observed were ST-
segment elevation in 3 (25%), pathological Q waves in 3(25%),
mainly in the leads V1-4.ST-segment depression was found in 4
patients (30%),3 patients (25%) exhibited T-wave inversion
without ST-segment shift.3 patients presented with cardiogenic
shock and 1 patient with ventricular tachycardia. Echocardio-
graphic parameters mean ± SD LV end-diastolic volume was
(115.9±4.0 mL) mean ± SD LV ejection fraction was (28.2%±2.5%).
None of the patients had an E/Em ratio of more than 15. In all 12
patients, left ventricular systolic function recovered completely
within three weeks. The systolic strain rate was decreased from
base to apex, but the early diastolic strain rate from base to apex
was marginally reduced (+3±0.5).
Conclusion: In patients with suspected ABS, clinical history of
acute physical/emotional stress with ECG changes mimicking
ischemia/infarct, echocardiographic systolic/diastolic paradox
with or without contrast echocardiography is helpful in catego-
rization of these patients.
Study of the role of ivabradine in acute heart
failure
Vikas Singh, Pramod Kumar, Ajay Kr Sinha
Paras HMRI Hospital, India
Background: Ivabradine is a drug which acts by selectively
blocking If current in the SA Node. It is approved for use in chronic
congestive heart failure. In patients with acute decompensated
systolic heart failure, tachycardia could be either a compensatory
mechanism or contribute to worsening heart failure. There are
situations where using a beta blocker is not an option.The present
study was planned to assess the feasibility, safety and efficacy of
using Ivabradine in acute heart failure.
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Methods: A retrospective analysis of 28 patients of acute heart
failure (all due to different spectrum of acute coronary syndrome)
in whom ivabradine was used was done. All of them had an
ejection fraction of <50%, resting heart rate >70 bpm and SBP> 100
mm Hg without inotropes. The patients were receiving standard
guideline directed therapy including beta blockers wherever
indicated. Ivabradine was started in a dose of 2.5 mg BD and
increased upto 7.5 mg BD in accordance with the patient’s clinical
condition. The patient’s clinical parameters were recorded at the
time of initiation of Ivabradine and 24-hours and 7 days after
initiation of therapy.
Results: A total of 28 patients (mean age 60.3 years, 20 males)
constituted the study group. Baseline mean Heart rate (HR) was 96
(70-128) bpm and systolic Blood pressure (SBP) was 110 mm
Hg(100-134mm Hg). Patients in NYHA II, III and IV numbered 19, 9
and 0 respectively when the therapy with ivabradine was started.
HR decreased by 2.7 ± 0.2 bpm after 24 hours (p¼NS) and 14.3 ± 7.2
bpm at day 7 (p ¼ 0.008). The systolic blood pressure decreased by
2.4mmHg after 24 hours (p¼NS) and 4.1mmHg at day 7 (p¼0.091)
. Patients in NYHA class II and III at 24 hours was 20 and 8
respectively. At 7 days, 8 patients were in NYHA I, 17 in NYHA II
and 3 in NYHA III. No worsening of NYHA class was noted in any
patient at 7 days.
Conclusion: Initiating Ivabradine in patients of acute heart failure
during hospital stay is both safe and effective.
The safety and efficacy of renal denervation
therapy in chronic heart failure patients using a
standard cardiac ablation catheter
A.K. Sharma, S.K. Dwivedi, R.K. Saran, S.C. Chandra
K.G.M.U. Lucknow, India
Background: Chronic heart failure is associated with sympathetic
activation characterised by elevated circulating norepinephrine
levels which are linked to cardiovascular morbidity andmortality.
Surgical renal denervation has been shown to improve both renal
and ventricular function, although all these studies have been
conducted on animal models so far. In humans the safety and
efficacy of renal denervation therapy has been studied in treat-
ment of drug resistant hypertension only. Limited data exist
regarding renal denervation therapy in chronic heart failure pa-
tients. All these studies have used specifically desingnedcathers
which are not cost effective especially in developing countries.
Our study is the first randomised study of renal denervation
done in patients of chronic heart failure using standard radio
frequency cardiac ablation cathers.
Aim and objective: To demonstrate the safety and efficacy of renal
denervation therapy in chronic heart failure patients using the
standard cardiac radiofrequency ablation catheter.
Method: Thirty eight patients with chronic heart faiulre with
LVEF< 40 % on optimal heart failure therapy were enrolled and
randomized into two group:
(a) interventional group (n ¼ 18) and; (b) conservative group (n ¼
20). Out of the 18 patients in the interventional arm, 15 underwent
successful bilateral renal denervation. In all these patients stan-
dard radio frequency cardiac ablation cather was used. Patients
were admitted for pre-procedure baseline assessments and in-
patient observation for 2 days following denervation. Follow up
was done at 1st week, one month, three months, six months and
one year.
Results: No significant haemodynamic disturbances were noted
during the acute phase post renal denervation. Over one year of
followup there was a non-significant trend to blood pressure
reduction (Dsystolic 5.2±5.9 mm Hg, p¼0.35; Ddiastolic 1.2± 3
mm Hg, p¼0.70). No hypotensive or syncopal episodes were re-
ported. Renal function remained stable (Dcreatinine 5.7±8.4
mmol/l, p¼0.52 and Durea 1.0±1.0 mmol/l, p¼0.33).
As compared to the conservative group, in the interventional
group there was a significant difference at 12 months of follow
with respect to increase in 6 min walk test(537±103meter to
603±119 vs 499± 98 to 533±99 p 0.001) , increase in LVEF(27.3±11 to
33.1±13 vs 28.1±12 to 30.1± 14 p< 0.001) and reduction in NT -pro
BNP levels(1896 ±79pg/ml to1324±67 pg/ml vs 1903±95 to 1765±89
p<0.001)
Conclusions: This study found no procedural or post procedural
complications following renal denervation in patients with
chronic systolic heart failure at 12 months follow-up. Results
suggested a significant improvement in interventional group as
compared to conservative group in terms of 6 min walk test, LVEF
and NT pro BNP levels.
Hence, to conclude sympathetic renal denervation is not only
safe but also efficient in patients of chronic heart failure and
standard cardiac ablation cathers can be as effective and safe as
specially designed cathers.
Prognostic correlation of quantitative cardiac
troponin T (cTnT) estimation in acute
decompensated heart failure patients admitted in
a tertiary care hospital
S. Singh, C. Misra, D.P. Sinha
IPGME&R, SSKM Hospital, Kolkata, India
Background: Presence of hsTnT was also a strong independent
predictor of mortality and provided prognostic information in
heart failure patient increamental to that provided by other
powerful predictor of outcome like BNP.
Methods: In this study 100 patient of acute decompensated heart
failure who were admitted in the cardiology indoor of IPGME&R,
SSKM hospital kolkata between February 2012 to September 2013
were enrolled. It is prospective observational study.within 24
hours of admission quantitative serum analysis was done and the
positive were categorized as troponin T positive(>50ng/l) or
troponin T negative(>50ng/l).
Results: The study shows significant number of patients(n¼66)
were positive for hsTnT. Systolic blood pressure is reduced sig-
nificantly(p<0.001) on follow up study in hsTnT positive patients.
FBS(>126mg/dl) is significantly increased on admission in hsTnT
positive patients(131.4+42.9) in compared to hsTnT negative
patients.(mean+SD¼98+33.2) (p¼0.049). LVID(d) is singificantly
increased at admission, discharge and follow up study. The
reduction of EF(%) is statistically significant(p¼0.03CI¼0.75 to 0.94
and odd ratio 0.84) in the three months follow up study. Duration
of stay in hospital is more in hsTnT positive patients than
troponin negative patients as detailed in descriptive study above.
The value become statistically significant in our study(p¼0.001).
Conclusion: The patients with troponin T positivity show higher
mortality (both in hospital and outside) and recurrent hospitali-
zation in comparison with troponin T negative patients. Duration
of stay in hospital is higher for hsTnT positive patients when
compared with troponin negative patients. NYHA class and
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